Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo plus Rituximab in First-line Follicular Lymphoma
NCT03245021Phase 1Active, not recruiting
- Start
- Sep 2017
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in follicular lymphoma (FL). Primary endpoint: Proportion of toxicity grade 3 or higher per CTCAE v4.0 at 16 weeks. Started Sep 2017; status: active, not recruiting.
02
Drugs
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03245021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245021.